US2011311531A1PendingUtilityA1
Immunotherapy of autoimmune disorders using antibodies which target b-cells
Est. expiryJun 9, 2019(expired)· nominal 20-yr term from priority
A61P 7/06A61P 5/14A61P 35/00A61P 37/06A61P 7/04A61P 31/12A61P 3/10A61P 9/00A61P 37/00A61P 37/02A61P 25/28A61P 25/00A61P 29/00A61K 38/00A61P 19/08C07K 16/2896C07K 2317/24A61K 2039/505A61K 2039/507A61P 21/00A61P 1/04A61P 11/00C07K 16/2887A61K 47/6849C07K 16/2803A61P 21/04A61P 1/16A61K 45/06A61K 39/3955A61P 19/02C07K 16/28A61P 19/00A61P 13/12A61K 47/6813A61K 39/395
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.
Claims
exact text as granted — not AI-modified1 . A method of treating an autoimmune disease in a subject comprising administering a human, humanized, chimeric or murine anti-CD 20 antibody which binds human CD 20 and an anti-TNFα antagonist or anti-IL-1 antagonist.
2 . A method according to claim 1 , wherein said anti-TNFα or anti-IL-1 antagonist is administered before said anti-CD 20 antibody.
3 . A method according to claim 1 , comprising administering an anti-CD 20 antibody and an anti-TNFα antagonist.
4 . A method according to claim 3 , wherein said anti-TNFα antagonist is administered before said anti-CD 20 antibody.
5 . A method according to claim 1 , wherein said autoimmune disease is rheumatoid arthritis.
6 . A method according to claim 1 , wherein said autoimmune disease is rheumatoid arthritis.
7 . A method according to claim 1 , wherein said anti-TNFα antagonist is etanercept.
8 . A method according to claim 7 , wherein said autoimmune disease is rheumatoid arthritis.
9 . A method according to claim 7 , wherein said anti-CD 20 antibody is a chimeric or humanized antibody.
10 . A method according to claim 9 , wherein said subject is a subject that has failed therapy with methotrexate.
11 . A method according to claim 1 , wherein said anti-CD 20 antibody is a naked antibody.
12 . A method according to claim 1 , wherein said anti-TNFα or anti-IL-1 antagonist is administered after said anti-CD 20 antibody.
13 . A method according to claim 1 , wherein said anti-TNFα or anti-IL-1 antagonist is administered concurrently with said anti-CD 20 antibody.
14 . A method according to claim 3 , wherein said anti-TNFα antagonist is administered after said anti-CD 20 antibody.
15 . A method according to claim 3 , wherein said anti-TNFα antagonist is administered concurrently with said anti-CD 20 antibody.
16 . A method according to claim 1 , comprising administering an anti-CD 20 antibody and an anti-IL-1 antagonist.
17 . A method according to claim 16 , wherein said anti-IL-1 antagonist is administered before said anti-CD 20 antibody.
18 . A method according to claim 16 , wherein said anti-IL-1 antagonist is administered after said anti-CD 20 antibody.
19 . A method according to claim 16 , wherein said anti-IL-1 antagonist is administered concurrently with said anti-CD 20 antibody.
20 . A method according to claim 1 , wherein said anti-TNFα antagonist is an anti-TNFα antibody which binds human TNFα and said anti-IL-1 antagonist is an anti-IL-1 antibody.
21 . A method according to claim 1 , comprising administering an anti-CD 20 antibody and a human, humanized, chimeric or murine anti-TNFα antibody which binds human TNFα.
22 . A method according to claim 1 , comprising administering an anti-CD 20 antibody and a human, humanized, chimeric or murine anti-IL-1 antibody.
23 . A method according to claim 1 , wherein said anti-TNFα antagonist is infliximab.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.